Research progress of adoptive cell therapy in acute leukemia
10.3969/j.issn.1671-8348.2025.06.028
- VernacularTitle:过继性T细胞疗法在急性白血病中的研究进展
- Author:
Yifan HE
1
;
Shuhui XU
;
Zengzheng LI
;
Yajie WANG
Author Information
1. 昆明理工大学医学院,昆明 650500
- Keywords:
adoptive cell immunotherapy;
acute leukemia;
chimeric antigen receptor;
immune cells;
re-search progress
- From:
Chongqing Medicine
2025;54(6):1442-1446
- CountryChina
- Language:Chinese
-
Abstract:
Acute leukemia is a common hematological malignancy.Conventional chemotherapy,targe-ted drug therapy,hematopoietic stem cell transplantation and other treatment methods have made progress,but the mortality rate of patients after recurrence is still high.Adoptive cell therapy(ACT)has emerged as an effective therapeutic option for acute leukemia,particularly chimeric antigen receptor(CAR)T-cell therapy,which has demonstrated remarkable efficacy in treating B-cell acute lymphoblastic leukemia(B-ALL)and ma-lignant lymphoma.However,CAR-T cell therapy may induce cytokine release syndrome.Recent studies have highlighted the potent anti-leukemia effects of CAR-NK cell therapy.This review summarizeed the research progress of ACT employing various immune cells targeting different antigens in the treatment of acute leukemia.
